Latest / Stock Movers / Synaptics Rises, Lumentum Falls, Acadia Pharma Jumps on Positive CHMP Drug Opinion
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market. Harnessing the power of Bloomberg data.
- 0:16Speaker 3: Let's take a look at some of the stocks on
- 0:18Speaker 3: the move today. We can do that with Bloombergs, Billy
- 0:20Speaker 3: Lip Stalts, Billy. What are you looking at today?
- 0:22Speaker 1: I want to start with a bit of a merger
- 0:24Speaker 1: move on Friday here on Semi tickern right now down
- 0:28Speaker 1: eighteen percent, while Synaptics ticker SYNA up about to little
- 0:34Speaker 1: more than two percent. This comes after an all stock
- 0:37Speaker 1: deal that will combine the two companies, obviously, with on
- 0:39Speaker 1: Semi acquiring Synaptics about six point two billion dollars, so
- 0:43Speaker 1: Synaptics holders will get one point three to five shares
- 0:46Speaker 1: of on Semi. Maybe a bit of your normal arbitrage
- 0:49Speaker 1: trade as we see the acquirer who's going to get
- 0:51Speaker 1: diluted down under a bit of pressure, is ours kind
- 0:54Speaker 1: of try to profit off of that spread. The one
- 0:57Speaker 1: thing that does stand out from this deal obviously in
- 0:58Speaker 1: the semiconductor space, but also the fact that, according to
- 1:01Speaker 1: analysts for on this applicated, this acquisition would push it
- 1:05Speaker 1: more towards the edge within AI, so thinking about smartphones
- 1:08Speaker 1: other actual devices in a way from building out data centers.
- 1:11Speaker 1: So the bullish kind of perspective as it relates to
- 1:14Speaker 1: on is that this does expand their tam as opposed
- 1:17Speaker 1: to just really diving deeper into data centers. Again, just
- 1:19Speaker 1: given all the back and forth on are we overbuilding
- 1:22Speaker 1: and what does this ultimately meet?
- 1:23Speaker 3: What I like about this deal is Snaptics is being
- 1:26Speaker 3: advised by UH Frankaptrones firm. Frank quap Chrone is the
- 1:31Speaker 3: leading technology m and a banker for the last thirty years.
- 1:34Speaker 3: His firm is advising, So still writing tickets in that space.
- 1:40Speaker 1: All right, Bailey, what else you guys for us? We
- 1:41Speaker 1: got some chip stocks I see, I guess kind of
- 1:43Speaker 1: looking more broadly, want to focus on sand Disc which
- 1:46Speaker 1: is down about four percent ticker SNDK. Obviously, we have
- 1:50Speaker 1: been seeing quite the volatility as it relates to the
- 1:52Speaker 1: Philadelphia Semi Conductor Index right now down about three percent,
- 1:55Speaker 1: but essentially back to where it was two days ago.
- 1:58Speaker 1: Even on a weekly basis, the socks is on pace
- 2:01Speaker 1: to drop six percent. That only be its worst weekly
- 2:04Speaker 1: performance since early March. So as much as we want
- 2:07Speaker 1: to talk about a big rally yesterday in the wake
- 2:09Speaker 1: of the Micron results. Now we're seeing a bit of
- 2:12Speaker 1: kind of risk off being dialed back investors, maybe bottom
- 2:14Speaker 1: feeding as it relates to software names selling some of
- 2:17Speaker 1: the big winners. You just got to keep in mind
- 2:18Speaker 1: the fact that the socks is up, I don't know,
- 2:20Speaker 1: ninety one percent year to date still, so even if
- 2:23Speaker 1: we are seeing a bit of red on the screen,
- 2:25Speaker 1: it's still an industry that's been kicking butt.
- 2:28Speaker 3: All right. One more a.
- 2:29Speaker 1: Kadia Pharmaceuticals to your acad You know, I love biotech
- 2:34Speaker 1: cover healthcare for the first batch of my years here
- 2:36Speaker 1: at Bloomberg. So that's stock right now, up double digits
- 2:39Speaker 1: of about twelve percent, biggest gain since last May. This
- 2:42Speaker 1: came after the European CHMP, which is equivalent to their
- 2:46Speaker 1: kind of FDA, gave a positive opinion for its drug
- 2:50Speaker 1: to treat symptoms of red syndrome, that is a rare
- 2:53Speaker 1: disease that kind of affects development of women or young
- 2:57Speaker 1: young ladies. This is a reversal though, so this is
- 3:00Speaker 1: a group that really was negative on the drug debut before,
- 3:05Speaker 1: but then kind of reverse that that normally does not
- 3:07Speaker 1: happen with these agencies. So looking at the Wall Street reaction,
- 3:10Speaker 1: positive update obviously as it relates to the potential for
- 3:13Speaker 1: sales of this drug in the European Union and what
- 3:16Speaker 1: that could ultimately mean Again biotech, a lot of risk,
- 3:18Speaker 1: a lot of reward. But right now at Kadia one
- 3:20Speaker 1: of the high.
- 3:21Speaker 2: Flyers this stock Movers report from Bloomberg Radio. Check back
- 3:26Speaker 2: with us throughout the day for the latest roundup of
- 3:28Speaker 2: companies making news on Wall Street and for the latest
- 3:31Speaker 2: market moving headlines. Listen to Bloomberg Radio Live, catch us
- 3:36Speaker 2: on YouTube, Bloomberg dot com, and on Applecarplay and Android
- 3:39Speaker 2: Auto with the Bloomberg Business app.